Instil Bio(US:TIL) Prnewswire·2026-01-09 03:16Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Instil Bio, Inc. and its officers or directors [1] Group 1: Company Developments - On January 6, 2026, Instil announced that its subsidiary, Axion Bio, Inc., will discontinue the clinical development of AXN-2510 and terminate its collaboration agreement with ImmuneOnco Biopharmaceuticals [2] - Following this announcement, Instil's stock price dropped by $5.63 per share, representing a decline of 45.81%, closing at $6.66 per share on the same day [2] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3]